HYUNJEONG CHO

Dr. HYUNJEONG CHO

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2024 in Life
Verified
Journal Article
Open access
HCHYUNJEONG CHO
HYUNJEONG CHO
JLJong-Min Lee
Jong-Min Lee
SPSung Ho Park
Sung Ho Park
JPJun-Bum Park
Jun-Bum Park
NJNa Young Jung
Na Young Jung
This retrospective study aimed to evaluate the impact of radiation dose on the outcomes of stereotactic radiosurgery (SRS) for benign meningiomas and determine an optimal dosing strategy for balancing tumor control and treatment-related toxicity. Clinical data of 147 patients with 164 lesions treated between 2014 and 2022 were reviewed. Primary outcomes included progression-free survival (PFS), local control rate (LCR), and radiation-induced toxicity, with secondary outcomes focusing on LCR and radiation-induced peritumoral edema (PTE) in two dose groups (≥14 Gy and <14 Gy). The results revealed a median follow-up duration of 47 months, with 1-year, 2-year, and 5-year PFS rates of 99.3%, 96.7%, and 93.8%, respectively, and an overall LCR of 95.1%. Radiation-induced toxicity was observed in 24.5% of patients, primarily presenting mild symptoms. Notably, no significant difference in LCR was found between the two dose groups (p = 0.628), while Group 2 (<14 Gy) exhibited significantly lower PTE (p = 0.039). This study concludes that SRS with a radiation dose < 14 Gy demonstrates comparable tumor control with reduced toxicity, advocating consideration of such dosing to achieve a balance between therapeutic efficacy and safety.

1 January 2024 in Brain Tumor Research and Treatment
Verified
Journal Article
Open access
PDF file
HCHYUNJEONG CHO
HYUNJEONG CHO
SPSung Chan Park
Sung Chan Park
JLJong Min Lee
Jong Min Lee
NJNa Young Jung
Na Young Jung
JPJun Bum Park
Jun Bum Park
Cho HJ, et al. Brain Tumor Res Treat. 2024 Apr;12(2):148-151. https://doi.org/10.14791/btrt.2024.0018

17 April 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
HCHYUNJEONG CHO
HYUNJEONG CHO
JLJong Min Lee
Jong Min Lee
SPSung Ho Park
Sung Ho Park
JPJun Bum Park
Jun Bum Park
NJNa Young Jung
Na Young Jung
This retrospective study aimed to evaluate the impact of radiation dose on the outcomes of stereotactic radiosurgery (SRS) for benign meningiomas and determine an optimal dosing strategy for balancing tumor control and treatment-related toxicity. Clinical data of 147 patients with 164 lesions treated between 2014 and 2022 were reviewed. Primary outcomes included progression-free survival (PFS), local control rate (LCR), and radiation-induced toxicity, with secondary outcomes focusing on LCR and radiation-induced peritumoral edema (PTE) in two dose groups (≥14 Gy and <14 Gy). Results revealed a median follow-up duration of 47 months, with 1-year, 2-year, and 5-year PFS rates of 99.3%, 96.7%, and 93.8% respectively, and an overall LCR of 95.1%. Radiation-induced toxicity was observed in 24.5% of patients, primarily presenting mild symptoms. Notably, no significant difference in LCR was found between the two dose groups (P = 0.628), while Group 2 (<14 Gy) exhibited significantly lower PTE (P = 0.039). The study concludes that SRS with a radiation dose <14 Gy demonstrates comparable tumor control with reduced toxicity, advocating for consideration of such dosing to achieve a balance between therapeutic efficacy and safety.